Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer

JSKN003 granted another breakthrough therapy designation in China for the treatment of patients with HER2-positive...

Padcev (Enfortumab vedotin) plus Keytruda (Pembrolizumab) sBLA granted FDA priority review for treatment of certain...

Heidelberg Pharma’s lead ADC Candidate HDP-101 granted fast track designation by US FDA for the...

Takeda enters global strategic partnership with Innovent Biologics to bolster oncology pipeline with next-generation investigational...